IRIX (34) ITOC (35) NUWE (45) NXL (37) ⌘ Pro Terminal →

ENDRA Life Sciences Inc. (NDRA) — RQD Stock Rating Cockpit

$4.88 +2.95% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

ENDRA Life Sciences Inc. (NDRA) carries a Roarable Rating of D (Sell) with 48/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D • SELL / AVOID Cap $7.3M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERSELL / AVOID • D

2-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk C

Each axis scored 0–20

12M PRICE TARGET CONE-4.5% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for NDRA)Realized 20D OHLCV Swing Band: ±12.5%

RSI-14 MOMENTUMNEUTRAL RANGE

4230 Oversold · 70 Hot

ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)

3.80>3.0 Fortress Safe

PIOTROSKI F-SCOREWEAK QUALITY (1–4)

3 / 99-Pt Accounting

52-WEEK LASER RANGE48% OF RANGE

L: $3$4.88H: $7

1. Money & Cash Health● WEAK

Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: ERQD 6 / 20

2. Big Money & Insiders● TRIMMING

Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: D-RQD 17 / 40

3. Hidden Risks & Market Weather● WATCH

SEC fine-print scan & interest-rate fit

No major SEC filing blowups, though current interest rates and Fed liquidity call for normal position sizing.

Factor Grade: CRQD 25 / 40

MULTI-MODEL JEV QUANT JURY DELIBERATION

2-of-3 JEV AI Jury Bearish Warning on NDRA

Cash & Moat Bull AI

ROIC & Free Cash Flow Model

BEARISH (30)

-35.0% ROIC with 42.0% gross margin and 2.80% FCF yield.

SEC Forensic Auditor AI

10-K Accruals & Altman-Z Guard

BEARISH (50)

Altman-Z 4.20 and Piotroski 3/9 pass balance-sheet audit.

Whale & Macro Hawk AI

Options Skew, 13F & Fed NetLiq

NEUTRAL (53)

17/40 institutional & smart-money positioning score with 15/20 macro alignment.

Bull Case: Why Buyers Like NDRA

✓Established market leader in Health Care with deep daily trading liquidity.

Bear Case: What Could Go Wrong

!Company executives have done more routine share selling than personal cash buying lately.
!Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring NDRA)

✓Walkthrough of NDRA's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

NDRA // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +0.21%📐 HORIZONTAL RANGE

2026-10-30O $4.85H $4.88L $4.72C $4.88VOL 10.6K

RES: $6.82SUP: $4.29SMA50: $5.44SMA200: $4.81

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

NDRA Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 NDRA Butterfly Map → + Track NDRA →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on NDRA today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for NDRA. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for NDRA today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (NDRA)

Health Care Rank #396 of 1016 ⚔️ IRIX vs NDRA Full Matrix →

1. Head-to-Head Health Care Peer Comparison (NDRA vs. IRIX, ITOC, NUWE, NXL)

Industry: Biotechnology: Electromedical & Electrotherapeutic Apparatus (26 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, ENDRA Life Sciences Inc. (NDRA) ranks #396 by composite RQD confidence (48/100, grade D) and #919 by equity capitalization ($7.3M). Within this direct 5-issuer industry benchmark cohort, NDRA leads on earnings valuation at N/A trailing P/E, while NDRA leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. NDRA currently leads its immediate peer cohort in composite quantitative strength at 48/100 (D).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
NDRA ACTIVE ENDRA Life Sciences Inc.	D	48/100	—	—	-35.0%	+2.95%	$7.3M	Benchmark Subject
IRIX IRIDEX Corporation	E	34/100	—	36.5%	-35.0%	-2.92%	$12.7M	/irix-vs-ndra →
ITOC iTonic Holdings Ltd (Class A)	D-	35/100	—	62.6%	-35.0%	-4.99%	$20.9M	/itoc-vs-ndra →
NUWE Nuwellis Inc.	D	45/100	—	62.0%	-35.0%	+2.12%	$2.3M	/nuwe-vs-ndra →
NXL Nexalin Technology Inc.	D-	37/100	—	79.7%	-35.0%	0.00%	$1.9M	/nxl-vs-ndra →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001681682

In its most recent audited fiscal period (FY2025, filed 2025-12-31), ENDRA Life Sciences Inc. (NDRA) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$7.0M, operating cash flow of -$5.2M, and free cash flow of -$5.2M (+29.9% YoY). On the balance sheet, NDRA closed FY2025 with $3.9M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	-$7.0M	-$5.2M	-$5.2M	$3.9M	—
FY2024 (FY)	2024-12-31	$0	-$11.5M	-$7.4M	-$7.4M	$4.5M	—
FY2023 (FY)	2023-12-31	$0	-$10.1M	-$9.5M	-$9.5M	—	—

3. NDRA Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is NDRA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, ENDRA Life Sciences Inc. (NASDAQ: NDRA) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 48/100 at a spot price of $4.88 (+2.95% 1D, market cap $7.3M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 12/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 15/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, NDRA ranks #396 in composite RQD confidence.

How does NDRA compare to IRIX and ITOC in the Health Care sector?

Within the Health Care sector (Biotechnology: Electromedical & Electrotherapeutic Apparatus), NDRA carries a Roarable D (48/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, IRIX (IRIDEX Corporation) holds a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $12.7M) and ITOC (iTonic Holdings Ltd (Class A)) posts a D- grade (35/100 RQD, P/E N/A, ROIC -35.0%, cap $20.9M). Among the 5-stock peer group, NDRA leads on earnings multiple (N/A) while NDRA leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for NDRA?

Per NDRA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001681682), ENDRA Life Sciences Inc. generated $0 in revenue, -$7.0M in net income, and -$5.2M in free cash flow against $3.9M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is NDRA trading relative to its 50-day, 200-day, and 52-week technical levels?

NDRA last traded at $4.88 (+2.95% on volume of 14,642 shares), positioning the stock -10.29% below its 50-day simple moving average ($5.44) and +1.46% above its 200-day simple moving average ($4.81). Across its 52-week range of $2.96 to $6.95, NDRA sits at the 48.1% percentile with a 14-day RSI of 42.0 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($4.27 to $5.49).

NDRA Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Should I buy, hold, or sell NDRA stock right now?

ENDRA Life Sciences Inc. (NDRA) currently earns a Roarable Rating of D (Sell — SELL) with 48/100 RQD Confidence. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.

What is NDRA's 12-month price target and RQD AI Jury consensus?

NDRA's 12-month base price target is $4.66 (range $3.63 to $7.3), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

Direct Sub-Reports: NDRA RQD Cockpit NDRA 12M Forecast NDRA Earnings & Move NDRA Dividends & DRIP NDRA Insiders & 13F NDRA Whale Options NDRA Profit Sankey NDRA News & Why